SCRI is the only oncology research organization of its kind to offer end-to-end clinical trial site management, contract research services for biopharma and personalized medicine advisory services in one place.
Learn more about partnering with SCRI.
Innovative Research Organization
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. SCRI has conducted more than 750 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today.
Today's Clinical Trials, Tomorrow's Therapies
Since inception, SCRI has partnered with leading biopharmaceutical companies to conduct community-based clinical research in oncology – from early to late-stage clinical trial development – in hundreds of communities across the United States. SCRI’s research network brings together more than 1,300 physicians who are actively accruing patients to 1,000+ active clinical trials at more than 250 locations in 24 states across the U.S.
SCRI offers:
- End-to-end clinical trial site management all in one place – from contract research organization (CRO) services through SCRI Development Innovations
- Centralized clinical trial support services through our site management organization (SMO)
- Personalized Medicine program that transforms real-world data into actionable insights
- Services to improve clinical trial diversity through our Clinical Trial Access program